Senior Marketing Events Specialist, RapidAI
$75-110k
+ Stock options
Using AI to combat vascular & neurovascular conditions
Open for applications
Using AI to combat vascular & neurovascular conditions
201-500 employees
Open for applications
$75-110k
+ Stock options
201-500 employees
Company mission
To deliver software tools that healthcare professionals around the world can use to successfully identify and diagnose more cerebrovascular disorders than ever before possible.
Jump to section
Company mission
To deliver software tools that healthcare professionals around the world can use to successfully identify and diagnose more cerebrovascular disorders than ever before possible.
23% employee growth in 12 months
Our take
The rise of artificial intelligence has led to breakthroughs across a number of industries, including healthcare and medical technology. RapidAI combines medical imaging with artificial intelligence to deliver a range of solutions for combatting life-threatening vascular and neurovascular conditions more effectively.
Through the company's scalable and secure platform, hospitals can make better and faster clinical decisions surrounding stroke, aneurysm, pulmonary embolism and, most recently, intracranial haemorrhage. Built on intelligence gained from over 10 million scans, RapidAI brings a level of visibility never before possible, supporting doctors to improve health outcomes for their patients.
The company is extremely well-regarded in the space, and has won awards such as the 2023 MedTech Breakthrough Award for Best New Imaging Solution. It recently announced the raise of $75 million in growth investment which will be used to drive platform innovation towards supporting more conditions, as well as fund go-to-market functions to accelerate growth in new regions and product verticals.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Life-Insurance, plus Short-Term & Long-Term Disability
- Pre-Tax Commuter Benefits
- Employee Assistance Program
- 401K Retirement Plan
- Medical, Dental & Vision
Company values
- Trust
- Transparency
- Teamwork
Funding (last 2 of 3 rounds)
Jul 2023
$75m
SERIES C
Sep 2020
$25m
SERIES B
Total funding: $100.5m
Leadership
Dr. Greg Albers
(Chair & Scientific Lead)Director and co-founder of the Stanford Stroke Center since 1992. Is also the Coyote Foundation Professor of Neurology and Professor, by courtesy, of Neurosurgery at Stanford University Medical Center. Greg has authored over 450 articles on cerebrovascular disease topics.
Roland Bammer
(Technical Advisor)A serial entrepreneur with over 30 years of experience developing academic and commercial software. Co-Director of the Stanford 3D Lab. Professor of Radiology and Director of Research Excellence in Neuroimaging at the University of Melbourne, and Director of Quantitative Neuroimaging at the Royal Melbourne Hospital.